Bold claim: a frog-derived bacterium may deliver a dual-action, highly safe anticancer effect. A team led by Prof. Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST) has identified Ewingella americana, isolated from the intestines of Japanese tree frogs (Dryophytes japonicus), as possessing exceptionally potent anticancer activity. The discovery is reported in the international journal Gut Microbes.
Background context: interest in the gut microbiome and cancer has surged, with many efforts concentrating on indirect strategies like microbiome modulation or fecal microbiota transplantation. This study, however, adopts a distinct path: it isolates, grows, and directly administers individual bacterial strains intravenously to attack tumors, representing a novel therapeutic paradigm.
Scope of the study: researchers screened 45 bacterial strains drawn from the intestines of three amphibian species—the Japanese tree frog, the Japanese fire-belly newt (Cynops pyrrhogaster), and the Japanese grass lizard (Takydromus tachydromoides). Nine strains showed antitumor activity, with E. americana emerging as the standout in terms of therapeutic effect.
Significant therapeutic efficacy
In a mouse model of colorectal cancer, a single intravenous dose of E. americana produced complete tumor regression, achieving a 100% complete response rate. This level of efficacy markedly surpasses outcomes seen with current standard treatments, including immune checkpoint blockade (anti-PD-L1 antibodies) and liposomal doxorubicin.
Dual-action anticancer mechanisms
E. americana targets cancer through two complementary pathways:
- Direct cytotoxic effect: As a facultative anaerobe, E. americana preferentially localizes to the hypoxic tumor microenvironment and directly destroys cancer cells. Within 24 hours of administration, tumor-associated bacterial counts rise roughly 3,000-fold, facilitating rapid tumor destruction.
- Immune activation: The bacterial presence robustly engages the immune system, recruiting T cells, B cells, and neutrophils to the tumor site. Pro-inflammatory cytokines such as TNF-α and IFN-γ are produced, boosting immune responses and promoting cancer cell apoptosis.
Tumor-specific targeting
E. americana demonstrates tumor-specific accumulation, with no detectable colonization in healthy organs. This striking selectivity appears to arise from several synergistic factors:
- Hypoxic tumor environment favors anaerobic bacterial growth
- Tumor cells can express immunosuppressive signals (e.g., CD47) that create a niche permitting bacterial survival
- Abnormal tumor vasculature and leaky vessels facilitate bacterial extravasation
- Tumor-specific metabolites support selective bacterial proliferation
Safety profile
Comprehensive safety assessments indicate that E. americana exhibits:
- Rapid clearance from the bloodstream (half-life ~1.2 hours; undetectable by 24 hours)
- No colonization in major normal organs such as liver, spleen, lungs, kidneys, or heart
- Only transient, mild inflammatory responses that normalize within 72 hours
- No chronic toxicity observed over a 60-day monitoring period
Future directions
This work provides a proof-of-concept for a new cancer therapy leveraging natural bacteria. Ongoing research will explore:
- Efficacy across additional cancer types, including breast cancer, pancreatic cancer, and melanoma
- Safer, more effective administration methods, such as dose fractionation or intratumoral injections
- Potential synergy with existing immunotherapies and chemotherapy
Takeaway: this study highlights the untapped potential of biodiversity as a source for pioneering cancer therapies, offering new options for patients with cancers that resist conventional treatments.
Note: While the original study emphasizes exciting preclinical findings, clinical validation and safety assessments in humans are essential before any medical recommendations can be made. Always consult qualified healthcare professionals for medical advice and treatment decisions.
